Jae Yeong Cho
Overview
Explore the profile of Jae Yeong Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lee S, Lee H, Yoo S, Cho H, Youn J, Park S, et al.
Int J Heart Fail
. 2025 Feb;
7(1):32-46.
PMID: 39911570
Heart failure (HF) is a major cause of mortality and morbidity in South Korea, imposing substantial physical, emotional, and financial burdens on patients and society. Despite the high burden of...
3.
Park H, Lee N, Hwang C, Cho S, Choi G, Cho J, et al.
JACC CardioOncol
. 2024 Oct;
6(5):699-710.
PMID: 39479323
Background: The long-term prognosis after the discontinuation of cardioprotective therapy (CPT) in patients with cancer therapeutics-related cardiac dysfunction (CTRCD) that has shown improvement remains unclear. Objectives: This study aims to...
4.
Choi H, Kwon O, Kim S, Cho J, Bae E, Ma S, et al.
BMC Med Genomics
. 2024 Oct;
17(1):245.
PMID: 39375654
Background: Fabry disease is an X-linked lysosomal storage disease caused by the impairment of α-galactosidase A. The complex intronic haplotype (CIH) variants, located in promoter and intronic regulatory lesions, has...
5.
Cho H, Rhee S, Cho D, Jun J, Heo H, Cho S, et al.
Exp Mol Med
. 2024 Sep;
56(9):2052-2064.
PMID: 39261656
The regulatory role of the inhibitor of NF-kB kinase ε (IKKε) in postmyocardial infarction (MI) inflammation remains uncertain. Using an MI mouse model, we examined the cardiac outcomes of IKKε...
6.
Lee N, Kim K, Park J, Cho J, Cho S, Kim D, et al.
Mayo Clin Proc
. 2024 Aug;
99(10):1577-1588.
PMID: 39093271
Objective: To investigate the incidence, characteristics, and outcomes of COVID-19 vaccine-related pericarditis (VRP) without myocarditis, we analyzed nationwide Korean data. Patients And Methods: This is a retrospective nationwide report including...
7.
Ryu S, Jeong W, Hong G, Cho J, Lee S, Kim H, et al.
Front Cardiovasc Med
. 2024 Jul;
11:1424551.
PMID: 39036505
Background: The alpha-protein kinase 3 () gene (OMIM: 617608) is associated with autosomal recessive familial hypertrophic cardiomyopathy-27 (CMH27, OMIM: 618052). Recently, several studies have shown that monoallelic premature terminating variants...
8.
Lee C, Lee H, Yoon M, Chun K, Kong M, Jung M, et al.
Int J Heart Fail
. 2024 May;
6(2):56-69.
PMID: 38694933
Background And Objectives: The number of people with heart failure (HF) is increasing worldwide, and the social burden is increasing as HF has high mortality and morbidity. We aimed to...
9.
Kim E, Park S, Cho D, Youn J, Lee H, Lee H, et al.
Am J Cardiovasc Drugs
. 2024 Feb;
24(2):313-324.
PMID: 38413500
Background: The DAPA-HF and DELIVER trials demonstrated the clinical benefits of dapagliflozin in heart failure (HF) patients across the entire ejection fraction (EF) spectrum. However, further investigation is needed for...
10.
Kim E, Park S, Youn J, Lee H, Lee H, Cho H, et al.
J Korean Med Sci
. 2024 Jan;
39(1):e8.
PMID: 38193327
Background: The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved empagliflozin for reducing cardiovascular mortality and heart failure (HF) hospitalization in patients with both HF with...